OTCMKTS:CLVLY Clinuvel Pharmaceuticals (CLVLY) Stock Price, News & Analysis $7.35 0.00 (0.00%) As of 07/17/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartDividendNews and TrendsSEC Filings About Clinuvel Pharmaceuticals Stock (OTCMKTS:CLVLY) Get CLVLY alerts:Sign Up Key Stats Today's Range$7.28▼$7.5250-Day Range$6.92▼$7.4052-Week Range$5.98▼$9.00Volume36,763 shsAverage Volume3,028 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company headquartered in Melbourne, specializing in the development and commercialisation of photoprotective and phototherapeutic solutions. The company’s research centers on harnessing the skin’s natural photoprotective pathways by modulating the melanocortin system, with a view to addressing a range of skin disorders and conditions that are exacerbated by ultraviolet light exposure. The company’s flagship product, Scenesse (afamelanotide), is the first systemic photoprotective drug approved by both the European Medicines Agency and the U.S. Food and Drug Administration for the prevention of phototoxic reactions in patients with erythropoietic protoporphyria (EPP). Beyond EPP, Clinuvel maintains an active clinical pipeline exploring additional indications such as vitiligo, acute UV-induced DNA damage and other disorders of pigment regulation. Its proprietary formulations and delivery methods are designed to offer consistent, controlled dosing and improved patient outcomes. Clinuvel serves markets across Europe, North America and the Middle East, operating a manufacturing facility in Europe alongside regulatory and commercial offices abroad. The company’s commercial infrastructure supports ongoing growth in specialty dermatology clinics and hospitals, while the research and development arm continues to expand the therapeutic applications of its photomedicine technology. Clinuvel is guided by a management team with extensive experience in drug development, regulatory affairs and global product rollout.AI Generated. May Contain Errors. Read More Receive CLVLY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clinuvel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CLVLY Stock News HeadlinesCLINUVEL implements strategic reorganisation to refocus on U.S. marketsJuly 22, 2026 | globenewswire.comCLINUVEL’s ADS to commence trading on NasdaqJuly 20, 2026 | markets.businessinsider.comThe dollar reset no one told you aboutPorter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-year history, back in 1974 with a secret Saudi deal that reshaped an entire generation's wealth. Today, a landmark treaty called Pax Silica - signed by 13 nations in December 2025 and barely covered in the press - is at the center of what Fortune calls 'the biggest change to the world's relationship with the dollar' in a generation. The stocks to buy, the assets to avoid, and the moves to consider are outlined in Stansberry's new briefing.August 24 at 1:00 AM | Porter & Company (Ad)Clinuvel upgrades US listing to Nasdaq under ticker 'CUVL'July 20, 2026 | msn.comCLINUVEL's ADS to commence trading on NasdaqJuly 20, 2026 | globenewswire.comSCENESSE® approved for EPP in CanadaJuly 13, 2026 | globenewswire.comCLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo studyApril 24, 2026 | globenewswire.comCLINUVEL: advancing peptides for photomedicine and vitiligo care at AAD 2026April 15, 2026 | globenewswire.comSee More Headlines CLVLY Stock Analysis - Frequently Asked Questions How have CLVLY shares performed this year? Clinuvel Pharmaceuticals' stock was trading at $8.48 at the beginning of 2026. Since then, CLVLY shares have decreased by 13.3% and is now trading at $7.35. How do I buy shares of Clinuvel Pharmaceuticals? Shares of CLVLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today8/24/2026Next Earnings (Estimated)9/01/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorConsumer Discretionary Industry Diversified Consumer Services Sub-IndustrySpecialized Consumer Services Current SymbolOTCMKTS:CLVLY CIK1290877 Webwww.clinuvel.com Phone(139) 660-4900FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (OTCMKTS:CLVLY) was last updated on 8/24/2026 by MarketBeat.com Staff. From Our PartnersIn 2022, every resident of this state received $3,284Since 1982, Alaska has paid every resident an annual check from its oil wealth, $3,284 in 2022 alone, funded e...Freedom Financial | SponsoredI found Rolls-Royce at $2 - now I see the same setup againIn 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had wri...Monument Traders Alliance | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredBuy These Stocks Before August 31stKeith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwi...TradeSmith | SponsoredThe dollar just brokeBloomberg research shows the U.S. dollar's share of global reserves has fallen to the lowest level this centur...Porter & Company | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clinuvel Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Clinuvel Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.